Phathom announces VOQUEZNA tablets added to Express Scripts

Phathom Pharmaceuticals announced the placement of VOQUEZNA tablets for the treatment of adults with Erosive Esophagitis, commonly referred to as Erosive GERD, and relief of heartburn associated with Erosive Esophagitis on the Express Scripts national formularies, effective immediately. VOQUEZNA is the first and only FDA-approved potassium-competitive acid blocker, PCAB, and the first new class of Erosive GERD treatment to become available in the United States in over 30 years. Commercial access for VOQUEZNA tablets is now estimated at 60 million covered lives in the United States. “We are thrilled to announce VOQUEZNA has been added to Express Scripts’ national formularies, highlighting one of the largest pharmacy benefit management companies in the U.S. is now providing millions of patients the potential for immediate access to our novel treatment for Erosive GERD,” said Martin Gilligan, Chief Commercial Officer of Phathom. “This formulary placement aligns with our expectations of offering broad access with a single step through a generic proton pump inhibitor. Given that most Erosive GERD patients have already undergone treatment with a PPI, and many continue to express dissatisfaction with their current regimens, we are pleased with this outcome. Additionally, we are actively engaging with the other major PBMs and health plans to further increase coverage and ensure that patients suffering from Erosive GERD have widespread access to VOQUEZNA.”